Skip to main content
SpringerLink
Log in
Book cover

Atlas of the Prostate pp 25–39Cite as

Medical Management of Benign Prostatic Hyperplasia

  • Chapter

  • 255 Accesses

Abstract

With histologic evidence of benign prostatic hyperplasia (BPH) in nearly 50% of men aged 50 years, and prevalence rates increasing with age, BPH is the most common benign neoplasm of elderly men [1]. Bladder outlet obstruction resulting from the hyperplastic prostate is believed to be secondary to two mechanisms: 1) the static component or bulk obstruction caused by the enlarged prostate encroaching on the prostatic urethra, and 2) the dynamic component mediated by smooth muscle tone within the prostatic stroma. Traditionally, surgery has been the mainstay of treatment for symptomatic BPH. However, clinical practice guidelines developed by the Agency for Health Care Policy and Research and endorsed by the American Urological Association were released to serve as a guide for the diagnosis and treatment of patients with BPH [2]. A new edition of these guidelines will be forthcoming in 2003. Treatment is recommended for the majority of patients with moderate to severe symptoms as defined by the American Urological Association symptom score. Medical therapy is among the recommended treatment options. The availability of medical therapy, which is less invasive and therefore more appealing to many patients, has been associated with huge increases in the total number of patients treated compared with the previous era, when surgery was the only option.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Berry SJ, Coffey DS, Walsh PC: The development of human prostatic hyperplasia with age. J Urol 1984, 132: 474–479.

    PubMed  CAS  Google Scholar 

  2. Benign Prostatic Hyperplasia Guideline Panel: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, Number 8. Rockville, MD: US Department of Health and Human Services; 1994. [AHCPR publication no. 94–0582, February, 1994.1

    Google Scholar 

  3. Wasson JH, Bubolz TA, Lu-Yao GL, et al.: Transurethral resection of the prostate among Medicare beneficiaries: 1984 to 1997. J Urol 2000, 164: 1212–1215.

    Article  PubMed  CAS  Google Scholar 

  4. Miller TA: BPH Survey.

    Google Scholar 

  5. Scott-Levin: Source & Trade: Prescription audit: 2000.

    Google Scholar 

  6. Bostwick DG, Cooner WH, Denis L, et al.: The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992, 70:291–301.

    Article  PubMed  CAS  Google Scholar 

  7. Chute CG, Panser LA, Girman CJ, et al.: The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993, 150:85–89.

    PubMed  CAS  Google Scholar 

  8. Moon TD, Hagen L, Heisey D: Urinary symptomatology in younger men. Urology 1997, 50: 700–703.

    Article  PubMed  CAS  Google Scholar 

  9. Jacobsen SJ, Jacobson DJ, Girman C, et al.: Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted county study of urinary symptoms and health status. J Urol 1999, 162: 1301–1306.

    Article  PubMed  CAS  Google Scholar 

  10. Wasson JH, Reda DJ, Bruskewitz RC, et al.: A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995, 332: 75–79.

    Article  PubMed  CAS  Google Scholar 

  11. Flangian RC, Reda DJ, Wasson JH, et al.: 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998, 160:12–17.

    Article  Google Scholar 

  12. McConnell JD, Bruskewitz R, Walsh P, et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998, 338: 557–563.

    Article  PubMed  CAS  Google Scholar 

  13. Nickel JC: The Canadian PROSPECT Study Group: placebo therapy in benign prostatic hyperplasia [abstract]. BrJ Uro! 1997, 80 (suppl): 194.

    Google Scholar 

  14. Hansen BI, Meyerhoff HH, Nordling J, et al.: Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. Scand J Urol Nephro11996, 30: 373–377.

    Article  PubMed  Google Scholar 

  15. Barry MJ, Fowler FJ, O’Leary MP, et al.: The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992, 148: 1549–1557.

    PubMed  CAS  Google Scholar 

  16. Isaacs JT, Coffey DS: Changes in DHT metabolism associated with the development of canine benign prostatic hyperplasia. Endocrinology 1981, 108:445–453.

    Article  PubMed  CAS  Google Scholar 

  17. Gabrilove JL, Levine AC, Kirschenbaum A, Droller M: Effect of long-acting gonadotropin-releasing hormone (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1989, 69: 629–632.

    Article  PubMed  CAS  Google Scholar 

  18. Eri LM, Tveter KJ: A prospective, placebo-controlled study of luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol 1993, 150: 359–364.

    PubMed  CAS  Google Scholar 

  19. Stone NN, Ray PS, Smith JA, et al.: A double-blind randomized controlled study of the effect of flutamide on benign prostatic hypertrophy: clinical efficacy [abstract]. J Urol 1989, 141: 240A.

    Google Scholar 

  20. Eri LM, Tveter KJ: A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J Uro! 1993, 150: 90–94.

    CAS  Google Scholar 

  21. Coffey D: The molecular biology, endocrinology and physiology of the prostate and seminal vesicles. In Campbell’s Urology, edn 6. Edited by Walsh PC et al. Philadelphia: WB Saunders; 1992: 221–266.

    Google Scholar 

  22. Cabot AT: The question of castration for enlarged prostate. Ann Surg 1896, 24: 265–309.

    Article  PubMed  CAS  Google Scholar 

  23. White JW: The results of double castration in hypertrophy of the prostate. Ann Surg 1895, 22: 1–80.

    Article  PubMed  CAS  Google Scholar 

  24. Schroder FH, Westerhof M, Bosch RJL, Kurth KH: Benign prostatic hyperplasia treated by castration or the LH-RH analogue Buserelin: a report of 6 cases. Eur Urol 1986, 12: 318–321.

    Google Scholar 

  25. Imperato-McGinley J, Guevro L, Gauteri T, Petersen RE: Steroid 5-a-reductase deficiency in a man: an inherited form of pseudohermaphroditism. Science 1974, 186: 1213–1215.

    Article  PubMed  CAS  Google Scholar 

  26. Imperato-Mcginley J, Gauteri T, Zirinsky K, et al.: Prostate visualization studies in males, homozygous and heterozygous with 5a-reductase deficiency. J Clin Endocrinol Metab 1992, 75:1022–1026.

    Article  PubMed  CAS  Google Scholar 

  27. Walsh PC, Madden JD, Harrod MJ, et al.: Familial incomplete male pseudohermaphroditism type II. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974, 291: 944–949.

    Article  PubMed  CAS  Google Scholar 

  28. Coffey DS: The endocrine control of normal and abnormal growth of the prostate. In Urologic Endocrinology. Edited by Rajfer J. Philadelphia: WB Saunders; 1986: 170–193.

    Google Scholar 

  29. Thigpen AE, Davis DL, Milatovitch A, et al.: Molecular genetics of steroid 5areductase-2 deficiency. J Clin Invest 1992, 90:799–809.

    Article  PubMed  CAS  Google Scholar 

  30. Liang T, Cascieri MA, Cheung AH, et al.: Species differences in prostatic steroid 5a-reductases of rat, dog and human. Endocrinology 1985, 117:571–579.

    Article  PubMed  CAS  Google Scholar 

  31. Brooks JR, Berman D, Glitzer MS, et al.: Effect of a new 5a-reductase inhibitor on size, histologic characteristics, and androgen concentrations of the canine prostate. Prostate 1982, 3: 35–44.

    Article  PubMed  CAS  Google Scholar 

  32. McConnell J, Akakura K, Bartsch G, et al.: Hormonal treatment of benign prostatic hyperplasia. In The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH), Proceedings 2. Edited by Cocket ATK, Khourg S, Aso Y, et al. Paris: Scientific Communications International; 1993: 417.

    Google Scholar 

  33. Vermeulen A, Giagulli VA, Schepper PD, et al.: Hormonal effects of an orally active 4-azosteroid inhibitor of 5-a reductase in humans. Eur Urol 1991, 20 (suppl 2): 82–86.

    PubMed  Google Scholar 

  34. McConnell JD, Wilson JD, George FW, et al.: Finasteride, an inhibitor of 5areductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992, 74: 505–508.

    Article  PubMed  CAS  Google Scholar 

  35. Geller J: Effect of finasteride, a 5a-reductase inhibitor on prostatic tissue androgens and prostatic specific antigen. J Clin Endocrinol Metab 1990, 71: 1552–1555.

    Article  PubMed  CAS  Google Scholar 

  36. Bramson HN, Hermann D, Batchelor K, etal.: Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997, 282: 1496–1502.

    PubMed  CAS  Google Scholar 

  37. Gormley GJ, Stoner E, Bruskewitz RC, et al.: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992, 327: 1185–1191.

    Article  PubMed  CAS  Google Scholar 

  38. Stoner E: The clinical effects of a 5a-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 1992, 147: 1298–1302.

    PubMed  CAS  Google Scholar 

  39. The Finasteride Study Group: Finasteride (MK-406) in the treatment of benign prostatic hyperplasia. Prostate 1993, 22: 291–299.

    Article  Google Scholar 

  40. Boyle P, Gould AL, Roehrborn C: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996, 48: 398–405.

    Article  PubMed  CAS  Google Scholar 

  41. Jacobsen SJ, Jacobson DJ, Girman CJ, et al.: Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997, 158:481–487.

    Article  PubMed  CAS  Google Scholar 

  42. Arrighi HM, Metter EJ, Guess HA, Fozzard JL: Natural history of benign prostatic hyperplasia and risk of prostatectomy: the Baltimore longitudinal study of aging. Urology 1991, 38 (suppl): 4–8.

    Article  PubMed  CAS  Google Scholar 

  43. Guess HA, Heyse JF, Gormley GJ, et al.: Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia: results from the North American phase II clinical trial. Urol Clin North Am 1993, 20: 627–636.

    PubMed  CAS  Google Scholar 

  44. Lange PH: Is the prostate pill finally here ? N Engl J Med 1992, 327: 1234–1236.

    Article  PubMed  CAS  Google Scholar 

  45. Stoner E: Three year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. The Finasteride Study Group. Urology 1994, 43: 284–292.

    Article  PubMed  CAS  Google Scholar 

  46. Oesterling JE, Roy J, Agha A, et al.: Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Urology 1997, 50:13–18.

    Article  PubMed  CAS  Google Scholar 

  47. Physicians’ Desk Reference edn 52. Montvale, NJ: Medical Economics Company; 1998:447–3198.

    Google Scholar 

  48. Coffey DS, Walsh PC: Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990, 17: 461–475.

    PubMed  CAS  Google Scholar 

  49. Moore RJ, Gazak JM, Wilson JD: Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 beta-estradiol. J Clin Invest 1979, 63: 351–357.

    Article  PubMed  CAS  Google Scholar 

  50. Berry SJ, Strandberg JD, Saunders WJ, Coffey DS: The development of canine benign prostatic hyperplasia with age. Prostate 1986, 9: 363–373.

    Article  PubMed  CAS  Google Scholar 

  51. Barrack ER, Berry Si: DNA synthesis in the canine prostate: effects of androgen and estrogen treatment. Prostate 1987, 10: 45–56.

    Article  PubMed  CAS  Google Scholar 

  52. Habenicht UF, Tunn UW, Senge TH, et al.: Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors. J Steroid Biochem Mol Biol 1993, 44: 557–563.

    Article  PubMed  CAS  Google Scholar 

  53. Gingell JC, Knonagel H, Kurth KH, etal.: Placebo-controlled, double-blind study to test the efficacy of the aromatase inhibitor atamestance in patients with benign prostatic hyperplasia not requiring operation. J Urol 1995, 154: 399–401.

    Article  PubMed  CAS  Google Scholar 

  54. Schwinn DA: The role of at-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 2001, 88: 27–34.

    Article  PubMed  CAS  Google Scholar 

  55. Ruffolo RR, Hieble JP: a-Adrenoreceptors. Pharmacol Ther 1994, 61: 1–64.

    Article  PubMed  CAS  Google Scholar 

  56. Ruffolo R, Nichols A, Stadel J, Hieble J: Structure and function of the alphaadrenoreceptors. Pharmacol Rev 1991, 43: 475–505.

    PubMed  CAS  Google Scholar 

  57. Lepor H, Tang R, Meretyk S, Shapiro E: The alpha-adrenoreceptor subtypes in the human prostate. J Uro11993, 149: 640–642.

    CAS  Google Scholar 

  58. Stafford-Smith M, Shambra U, Wilson K, Page, et al.: at-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding at-adrenergic subtypes at four different levels. Mol Brain Res 1999, 63: 254–261.

    Article  Google Scholar 

  59. Fabricius PG, MacHannaford HM: Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. Br] Urol 1992, 70 (suppl): 10.

    Article  Google Scholar 

  60. Lepor H, Auerbach S, Puras-Baez A, et al.: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992, 148:1467–1474.

    PubMed  CAS  Google Scholar 

  61. Lepor H, Soloway M, Appell R, et al.: A double-blind randomized multicenter trial involving comparison of terazosin and placebo in patients with benign prostatic hyperplasia [abstract 215]. Proceedings of the 10th Congress of the European Association of Urologists. Genoa: European Association of Urologists; 1992: 309.

    Google Scholar 

  62. Brawer MK, Adams G, Epstein H: Terazosin in the treatment of benign prostatic hyperplasia: Terazosin Benign Prostatic Hyperplasia Study Group. Arch Fam Med 1993, 2: 929–935.

    Article  PubMed  CAS  Google Scholar 

  63. Debruyne FMJ, Lodewijk D, Arocena F, Kirk D: Efficacy of terazosin in benign prostatic hyperplasia from a randomized withdrawal International Terazosin Trial (ITT) [abstract 177]. J Ural 1995, 153 (suppl): 273A.

    Google Scholar 

  64. Roehrborn C, Oesterling JE, Auerbach S, et al.: The Hytrin Community Assessment Trial Study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996, 47: 159–168.

    Article  PubMed  CAS  Google Scholar 

  65. Gillenwater JY, Mobley DL: A sixteen week, double-blind, placebo-controlled, dose-titration study using doxazosin tablets for the treatment of benign prostatic hyperplasia (BPH) in normotensive males: a multicenter study group [abstract 447]. J Urol 1993, 149: 324A.

    Google Scholar 

  66. Janknegt RA, Chapple CR: Efficacy and safety of the al -blocker doxazosin in the treatment of benign prostatic hyperplasia: analysis of 5 studies: doxazosin study groups. Eur Urol 1993, 24: 319–326.

    PubMed  CAS  Google Scholar 

  67. Chapple CR, Carter P, ChristmasTJ, etal.: A three month double-blind study of doxazosin as treatment for benign prostatic outlet obstruction. BrJ Urol 1994, 74: 50–56.

    Article  CAS  Google Scholar 

  68. Holme BJ, Christensen MM, Rasmussen PC, etal.: 29-Week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia: a double-blind, placebo-controlled study. Scand J Urol Nephrol 1994, 28: 77–82.

    Article  Google Scholar 

  69. Fawzy A, Braun K, Lewis GP, etal.: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995, 154: 129–130.

    Article  Google Scholar 

  70. Gillenwater JY, Conn RL, Chrysant SG, etal.: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter trial. J Urol 1995, 154: 110–115.

    Article  PubMed  CAS  Google Scholar 

  71. Kirby RS: Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995, 46:182–186.

    Article  PubMed  CAS  Google Scholar 

  72. Wilde MI, McTavish D: Tamsulosin: a review of it pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs 1996, 52: 883–898.

    Article  PubMed  CAS  Google Scholar 

  73. Abrams P, Schulman CC, Vaage S: Tamsulosin, a selective al c-adrenoreceptor antagonist: a randomized, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). The European Tamsulosin Study Group. Br Urol 1995, 76: 325–336.

    Article  CAS  Google Scholar 

  74. Lepor H, Tamsulosin Investigator Group: Clinical evaluation of tamsulosin, a prostate selective al c-antagonist. J Urol 1995, 153 (suppl): 274A.

    Article  Google Scholar 

  75. Chapple CR, Wyndaele JJ, Nordling J, et al.: Tamsulosin, the first prostate-selective alpha 1A-adrenoreceptor antagonist: a meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996, 29: 155–167.

    PubMed  CAS  Google Scholar 

  76. Lowe FC, Tuttle J, Marks S, for the HYCAT Investigator Group: Blood pressure effects of men with prostatism concurrently treated with antihypertensives and terazosin. J Urol 1995, 153: 272A.

    Google Scholar 

  77. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al.: Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991, 337:1457–1461.

    Article  PubMed  CAS  Google Scholar 

  78. Hansen BJ, Nordling J, Mensink H, et al.: Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume: a multicentre, double-blind, placebo-controlled trial. Scand J Urol Nephrol 1994, 157:169–176.

    CAS  Google Scholar 

  79. Buzelin JM, Roth S, Geffriaud-Ricouard C, et al., and the ALGEBI study Group: Efficacy and safety of sustained release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997, 31: 190–198.

    PubMed  CAS  Google Scholar 

  80. Kerrebroeck P, Jardin A, Laval K, et al.: Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol2000, 37: 306–313.

    Article  PubMed  Google Scholar 

  81. Lepor H: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995, 45: 406–413.

    Article  PubMed  CAS  Google Scholar 

  82. Lepor H, Kaplan SA, Klimberg I, etal.: Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997, 157: 525–530.

    Article  PubMed  CAS  Google Scholar 

  83. Narayan P, Evans C, Moon T: Long-term safety and efficacy of tamsulosin. J Urol 2002 (in press).

    Google Scholar 

  84. Djavan B, Marberger M: A meta-analysis on the efficacy and tolerability of atadrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999, 36: 1–13.

    Article  PubMed  CAS  Google Scholar 

  85. Lepor H, Williford WO, Barry MJ, et al.: The Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group: the efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996, 335:533–539.

    Article  PubMed  CAS  Google Scholar 

  86. Walsh PC: Treatment of benign prostatic hyperplasia. N Engl J Med 1996, 335: 586–587.

    Article  PubMed  CAS  Google Scholar 

  87. Wilt TJ, Ishani A, Stark GT, et al.: Saw palmetto extracts for treatment of benign prostatic hyperplasia. JAMA 1998, 280: 1604–1614.

    Article  PubMed  CAS  Google Scholar 

  88. Astin J: Why patients use alternative medicine. JAMA 1998, 279: 1548–1553.

    Article  PubMed  CAS  Google Scholar 

  89. WiIt TJ, Macdonald R, Ishani A: (3-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int 1999, 83: 976–983.

    Google Scholar 

  90. Lowe F: Phytotherapy in the management of benign prostatic hyperplasia. Urology 2001, 58 (suppl 6A): 71–77.

    Article  PubMed  CAS  Google Scholar 

  91. Berges RR, Kassen A, Senge T: Treatment of symptomatic benign prostatic hyperplasia with ß-sitosterol: an 18-month follow-up. BJU Int 2000, 85: 842–846.

    Article  PubMed  CAS  Google Scholar 

  92. McConnell JD for the MTOPS Steering Committee: The long-term effects of medical therapy on the progression of BPH: results from the MTOPS trial [abstract]. J Urol 2002, 167 (suppl):A1042.

    Google Scholar 

Download references

Authors
  1. Timothy D. Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Urology, University of Wisconsin-Madison Medical School, Madison, Wisconsin, USA

    Reginald C. Bruskewitz MD (Professor of Surgery) (Professor of Surgery)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Current Medicine, Inc.

About this chapter

Cite this chapter

Moon, T.D. (2003). Medical Management of Benign Prostatic Hyperplasia. In: Bruskewitz, R.C. (eds) Atlas of the Prostate. Current Medicine Group, London. https://doi.org/10.1007/978-1-4615-6505-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6505-5_3

  • Publisher Name: Current Medicine Group, London

  • Print ISBN: 978-1-4615-6507-9

  • Online ISBN: 978-1-4615-6505-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation